Silicon Valley Takes on Big Pharma

Ben_HS

Ben Benoy

I don’t think there’s anyone who likes popping pills for an ailment. Internal chemistry is a delicate cocktail, after all.

Well, a partnership between two tech and healthcare juggernauts may soon do their part to end the “better living through chemistry” motto and skip the pills by moving from chemistry to technology.

Google’s parent company Alphabet (Nasdaq: GOOGL) has partnered with leading British pharmaceutical firm GlaxoSmithKline (NYSE: GSK) to launch a new “bioelectronics medicine” company.

Alphabet_Chart-vector.svg
Bioelectric medicine is a new field of research focusing on tiny implanted devices that alter a person’s electrical nerve signal to treat chronic conditions like arthritis, diabetes, and asthma.
Economist Harry S. Dent Jr. now has indisputable evidence of precisely where gold is heading next.

A Pretty Big Bet

Laying their reputations on the line, both companies forecast this new technology will foster the next medical revolution. Called Galvani Bioelectronics, the joint venture will receive $715 million in funding over the next seven years.

BEM-web-graphic-FINAL

Like all good risk-averse companies, GlaxoSmithKline (GSK) isn’t putting all their “tech eggs” in one basket solely with Alphabet. GSK announced the day before that they are also partnering with Apple (Nasdaq: AAPL) to leverage their medical research capability, called ResearchKit.

Apple, along with other traditional tech companies, are starting to diversify their portfolios into the healthcare industry. They’re focusing their deep knowledge of massive IT infrastructures, as well as computing, and applying this expertise to challenging medical issues.

As the healthcare industry goes digital, more medical breakthroughs occur through plain old computer data crunching.

Bigger Than an iPhone

With the data for a single human genome measuring roughly 100 gigabytes in size (average storage capacity for the top tier iPhone), medical companies simply require the data processing power associated with large IT companies.

Nerves

By applying genome data with highly targeted treatment options and stats culled from a patient’s medical history, plus regional health/lifestyle data and a fitness tracker, providers hope to build a better and more complete health picture.

Physicians have an uphill battle leveraging this data fully with their current tools. Alphabet, Apple, and even Microsoft hope to change that by offering their infrastructure to crunch these massive data sets for precision medicine.

Data points to make our medicine options more precise are growing at an exponential rate.

Enough to Make Your Skin Tingle

Engineers at Tufts University have been integrating microfluidics, electronics, and nanoscale sensors into suture threads.

These threads contain high-end electronics designed to suture down through multiple layers of skin and tissue.

1280px-Skin_layers.svg

Once sutured, the threads would provide wireless information on underlying tissue, in real time, to alert doctors of possible infections or relevant healing data.

Results in the Journal of Microsystems & Nanoengineering look genuinely promising for use in a variety of specific cases.

Bottom line: this technology would add one more calculated data point to everything else we currently utilize to provide a whole health picture.

Bioelectronic treatments, smart sutures, and massive health data crunching will no doubt disrupt the current health and IT industries in the coming years.

Count on your Dent Research team to provide you the latest insights into technology that you can profit from for market plays.

Stay fierce,

Ben's Signature

 

 

 

Ben Benoy

Editor, BioTech Intel Trader

Hello, I'm Ben Benoy

Try my BioTech Intel Trader system for 90 days - risk free!

Based on the same techniques used by the Department of Defense to monitor online chatter, the system – known as Social Media Collective Intelligence or SMCI – behind the new service has helped Ben pinpoint, through paper trading, 112 trades covering 45 positions over the last year, and achieved a win rate of 82.2%!

If you decide to try Ben’s Biotech Intel Trader, here’s what you’ll get:

• The Strategy Report: Profiting from the Social Buzz on Biotech Stocks, which introduces you to the core philosophy of this strategy.

• A year’s worth of alerts – sent via email every Monday – giving you up to 36 market beating recommendations.

• Buy and sell alerts as warranted.

Uber of the Oceans

June 14, 2016: Shipping freight is a convoluted and doglegged process and Flexport is changing that one ship at a time.

Web for the World

May 27, 2016: The solution: really big balloons. It’s easy to take the Internet for granted. We carry most of the world’s…

Harry Dent’s Most Disturbing Prediction in Years

Harry Dent, one of the most respected economists in the industry, has uncovered a disturbing market event that could soon devastate millions of investors. In short, he has undeniable proof that one of the market’s safest and most popular investments is about to get slaughtered… and it will have dire consequences for those who don’t prepare right away.

For full details on the event Harry’s dubbed as the “Safe-Asset Slaughter”… and to ensure you escape the coming carnage, I urge you to watch this special presentation.

Click to Learn More
Categories: Markets

About Author

Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.